<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40949788</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-9368</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Metabolism open</Title><ISOAbbreviation>Metabol Open</ISOAbbreviation></Journal><ArticleTitle>Selective serotonin reuptake inhibitors and glucose metabolism in Alzheimer's disease and related dementias: A systematic review and meta-analysis of brain metabolic and adverse event data.</ArticleTitle><Pagination><StartPage>100389</StartPage><MedlinePgn>100389</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100389</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.metop.2025.100389</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for depression in Alzheimer's disease (AD), however their effects on glucose metabolism remain poorly understood. We conducted a systematic review and meta-analysis to evaluate SSRI effects on brain glucose metabolism and metabolic adverse events in AD patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Following PRISMA 2020 guidelines, we searched multiple databases up to July 11, 2025 for studies investigating SSRI effects on glucose-related outcomes in AD patients. Despite significant heterogeneity in study designs and populations, we performed meta-analyses for adverse events and coordinate-based meta-analysis for neuroimaging data. We performed meta-analyses for adverse events and coordinate-based meta-analysis for neuroimaging data. Advanced Bayesian hierarchical modeling and Markov simulations projected long-term metabolic outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Twelve studies with total included 7143 participants met our inclusion criteria, including nine randomized controlled trials and three observational studies. Brain FDG-PET revealed SSRI use restored dorsal raphe nucleus hypometabolism (standardized mean difference 0.87, 95&#xa0;% CI: 0.52-1.22, P-value&#xa0;=&#xa0;0.001). Meta-analysis demonstrated increased gastrointestinal adverse events (risk ratio 2.15, 95&#xa0;% CI: 1.68-2.76, P-value&lt;0.001, with moderate between-study heterogeneity), with sertraline showing highest rates. Citalopram 30&#xa0;mg provided significant weight loss protection (risk ratio 0.13, 95&#xa0;% CI: 0.02-0.98, P-value&#xa0;=&#xa0;0.02), though this exceeds the recommended 20&#xa0;mg maximum dose for elderly patients due to cardiac safety considerations. Long-term diabetes incidence showed no increased risk (hazard ratio 0.75, 95&#xa0;% CI: 0.50-1.12, P-value&#xa0;=&#xa0;0.15). Bayesian modeling revealed 85&#xa0;% probability of beneficial brain metabolic effects and 89&#xa0;% probability of citalopram superiority for weight protection.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">SSRIs restore brain glucose metabolism in AD patients while causing manageable peripheral metabolic effects. Citalopram appears the best for weight-sensitive patients, while sertraline requires gastrointestinal monitoring. These findings support SSRI safety for metabolic outcomes in AD treatment, however longer-term studies with controlled metabolic outcomes are needed to confirm our findings. The observed citalopram weight protection benefit was documented at 30&#xa0;mg daily, which exceeds recommended dosing limits for elderly patients due to cardiac safety concerns.</AbstractText><CopyrightInformation>&#xa9; 2025 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alzenaidi</LastName><ForeName>Faisal</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>College of Medicine, Qassim University, Buraydah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldoweesh</LastName><ForeName>Osama</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>College of Medicine, Qassim University, Buraydah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alghofaili</LastName><ForeName>Salman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>College of Medicine, Qassim University, Buraydah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fadel</LastName><ForeName>Abdulaziz</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>College of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali Awad Lasloom</LastName><ForeName>Razan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>College of Medicine, Najran University, Najran, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alharbi</LastName><ForeName>Dhay</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Buraydah Colleges, Buraydah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almalki</LastName><ForeName>Faris</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hospital Pharmacist, United Doctors Hospital, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad Alkhairi</LastName><ForeName>Atheer</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>College of Medicine, Umm Al-Qura University, Al-Qunfudah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alharbi</LastName><ForeName>Maram</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed Alhamdan</LastName><ForeName>Norah</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Consultant of Neurology, Department of Medicine, Qassim University, Buraydah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azzam</LastName><ForeName>Ahmed Y</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Director of Clinical Research and Clinical Artificial Intelligence, ASIDE Healthcare, Lewes, DE, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Metabol Open</MedlineTA><NlmUniqueID>101767753</NlmUniqueID><ISSNLinking>2589-9368</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Dementia</Keyword><Keyword MajorTopicYN="N">Glucose metabolism</Keyword><Keyword MajorTopicYN="N">Metabolism</Keyword><Keyword MajorTopicYN="N">Selective serotonin reuptake inhibitors</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests or conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>12</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>7</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40949788</ArticleId><ArticleId IdType="pmc">PMC12423674</ArticleId><ArticleId IdType="doi">10.1016/j.metop.2025.100389</ArticleId><ArticleId IdType="pii">S2589-9368(25)00045-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>2024 alzheimer's disease facts and figures. Alzheimer's Dementia : the journal of the Alzheimer's Association. 2024:3708. doi: 10.1002/alz.13809. [PMID: 38689398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.13809</ArticleId><ArticleId IdType="pmc">PMC11095490</ArticleId><ArticleId IdType="pubmed">38689398</ArticleId></ArticleIdList></Reference><Reference><Citation>Byers A.L., Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol. 2011:323. doi: 10.1038/nrneurol.2011.60. [PMID: 21537355 10.1038/nrneurol.2011.60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.60</ArticleId><ArticleId IdType="pmc">PMC3327554</ArticleId><ArticleId IdType="pubmed">21537355</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafsari F.S., Jessen F. Depression-an underrecognized target for prevention of dementia in alzheimer's disease. Transl Psychiatry. 2020:160. doi: 10.1038/s41398-020-0839-1. [PMID: 32433512 10.1038/s41398-020-0839-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-020-0839-1</ArticleId><ArticleId IdType="pmc">PMC7239844</ArticleId><ArticleId IdType="pubmed">32433512</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca C., Ettcheto M., Bicker J., Fernandes M.J., Falc&#xe3;o A., Camins A., Fortuna A. Under the umbrella of depression and alzheimer's disease physiopathology: can cannabinoids be a dual-pleiotropic therapy? Ageing Res Rev. 2023 doi: 10.1016/j.arr.2023.101998. [PMID: 37414155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2023.101998</ArticleId><ArticleId IdType="pubmed">37414155</ArticleId></ArticleIdList></Reference><Reference><Citation>Safiri S., Ghaffari Jolfayi A., Fazlollahi A., Morsali S., Sarkesh A., Daei Sorkhabi A., Golabi B., Aletaha R., Motlagh Asghari K., Hamidi S., Mousavi S.E., Jamalkhani S., Karamzad N., Shamekh A., Mohammadinasab R., Sullman M.J.M., &#x15e;ahin F., Kolahi A.A. Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges. Front Med. 2024 doi: 10.3389/fmed.2024.1474043. [PMID: 39736972.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2024.1474043</ArticleId><ArticleId IdType="pmc">PMC11682909</ArticleId><ArticleId IdType="pubmed">39736972</ArticleId></ArticleIdList></Reference><Reference><Citation>Correia A.S., Vale N. Antidepressants in alzheimer's disease: a focus on the role of mirtazapine. Pharmaceuticals. 2021 doi: 10.3390/ph14090930. [PMID: 34577630 10.3390/ph14090930.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14090930</ArticleId><ArticleId IdType="pmc">PMC8467729</ArticleId><ArticleId IdType="pubmed">34577630</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishibashi K., Wagatsuma K., Ishiwata K., Ishii K. Alteration of the regional cerebral glucose metabolism in healthy subjects by glucose loading. Hum Brain Mapp. 2016:2823. doi: 10.1002/hbm.23210. [PMID: 27061859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.23210</ArticleId><ArticleId IdType="pmc">PMC6867242</ArticleId><ArticleId IdType="pubmed">27061859</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H.R., Sheng L.Q., Pan P.L., Wang G.D., Luo R., Shi H.C., Dai Z.Y., Zhong J.G. Cerebral glucose metabolic prediction from amnestic mild cognitive impairment to Alzheimer's dementia: a meta-analysis. Transl Neurodegener. 2018:9. doi: 10.1186/s40035-018-0114-z. [PMID: 29713467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-018-0114-z</ArticleId><ArticleId IdType="pmc">PMC5911957</ArticleId><ArticleId IdType="pubmed">29713467</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebelos E., Rinne J.O., Nuutila P., Ekblad L.L. Brain glucose metabolism in health, obesity, and cognitive decline-does insulin have anything to Do with it? A narrative review. J Clin Med. 2021 doi: 10.3390/jcm10071532. [PMID: 33917464.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10071532</ArticleId><ArticleId IdType="pmc">PMC8038699</ArticleId><ArticleId IdType="pubmed">33917464</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z., Zhong C. Decoding alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Progress in neurobiology. 2013:21. doi: 10.1016/j.pneurobio.2013.06.004. [PMID: 23850509 10.1016/j.pneurobio.2013.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2013.06.004</ArticleId><ArticleId IdType="pubmed">23850509</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin S., Nam H.Y. Effect of obesity and osteocalcin on brain glucose metabolism in healthy participants. Brain Sci. 2023 doi: 10.3390/brainsci13060889. [PMID: 37371372.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci13060889</ArticleId><ArticleId IdType="pmc">PMC10296109</ArticleId><ArticleId IdType="pubmed">37371372</ArticleId></ArticleIdList></Reference><Reference><Citation>Soltani S., Dolatshahi M., Soltani S., Khazaei K., Rahmani M., Raji C.A. Relationships between brain glucose metabolism patterns and impaired glycemic status: a systematic review of FDG-PET studies with a focus on alzheimer's disease. Hum Brain Mapp. 2025 doi: 10.1002/hbm.70180. [PMID: 40033766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.70180</ArticleId><ArticleId IdType="pmc">PMC11876560</ArticleId><ArticleId IdType="pubmed">40033766</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonamine C.Y., Michalani M.L.E., Moreira R.J., Machado U.F. Glucose transport and utilization in the hippocampus: from neurophysiology to diabetes-related development of dementia. Int J Mol Sci. 2023 doi: 10.3390/ijms242216480. [PMID: 38003671 10.3390/ijms242216480.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms242216480</ArticleId><ArticleId IdType="pmc">PMC10671460</ArticleId><ArticleId IdType="pubmed">38003671</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantonen T., Pekkarinen L., Karjalainen T., Bucci M., Kalliokoski K., Haaparanta-Solin M., Aarnio R., Dickens A.M., von Eyken A., Laitinen K., Houttu N., Kirjavainen A.K., Helin S., Hirvonen J., R&#xf6;nnemaa T., Nuutila P., Nummenmaa L. Obesity risk is associated with altered cerebral glucose metabolism and decreased &#x3bc;-opioid and CB(1) receptor availability. Int J Obes. 2005;2022:400. doi: 10.1038/s41366-021-00996-y. [PMID: 34728775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41366-021-00996-y</ArticleId><ArticleId IdType="pmc">PMC8794779</ArticleId><ArticleId IdType="pubmed">34728775</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonogaki K. The regulatory role of the central and peripheral serotonin network on feeding signals in metabolic diseases. Int J Mol Sci. 2022 doi: 10.3390/ijms23031600. [PMID: 35163521.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23031600</ArticleId><ArticleId IdType="pmc">PMC8836087</ArticleId><ArticleId IdType="pubmed">35163521</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y., Li X., Zhou H., Zhou J. The serotonergic system dysfunction in diabetes mellitus. Front Cell Neurosci. 2022 doi: 10.3389/fncel.2022.899069. [PMID: 35910256.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2022.899069</ArticleId><ArticleId IdType="pmc">PMC9331500</ArticleId><ArticleId IdType="pubmed">35910256</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh C.M., Park S., Kim H. Serotonin as a new therapeutic target for diabetes mellitus and obesity. Diabetes &amp; metabolism journal. 2016:89. doi: 10.4093/dmj.2016.40.2.89. [PMID: 27126880 10.4093/dmj.2016.40.2.89.</Citation><ArticleIdList><ArticleId IdType="doi">10.4093/dmj.2016.40.2.89</ArticleId><ArticleId IdType="pmc">PMC4853228</ArticleId><ArticleId IdType="pubmed">27126880</ArticleId></ArticleIdList></Reference><Reference><Citation>Yabut J.M., Crane J.D., Green A.E., Keating D.J., Khan W.I., Steinberg G.R. Emerging roles for serotonin in regulating metabolism: new implications for an ancient molecule. Endocr Rev. 2019:1092. doi: 10.1210/er.2018-00283. [PMID: 30901029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/er.2018-00283</ArticleId><ArticleId IdType="pmc">PMC6624793</ArticleId><ArticleId IdType="pubmed">30901029</ArticleId></ArticleIdList></Reference><Reference><Citation>Zha W., Ho H.T.B., Hu T., Hebert M.F., Wang J. Serotonin transporter deficiency drives estrogen-dependent obesity and glucose intolerance. Sci Rep. 2017:1137. doi: 10.1038/s41598-017-01291-5. [PMID: 28442777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-01291-5</ArticleId><ArticleId IdType="pmc">PMC5430688</ArticleId><ArticleId IdType="pubmed">28442777</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Dong S., Liu C., Yang J., Rensen P.C.N., Wang Y. Serotonin signaling to regulate energy metabolism: a gut microbiota perspective. Life metabolism. 2025 doi: 10.1093/lifemeta/loae039. [PMID: 39926388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/lifemeta/loae039</ArticleId><ArticleId IdType="pmc">PMC11803461</ArticleId><ArticleId IdType="pubmed">39926388</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo Y.S., Lim H.K., Wang S.M., Bahk W.M. Clinical evidence of antidepressant effects of insulin and anti-hyperglycemic agents and implications for the pathophysiology of Depression-A literature review. Int J Mol Sci. 2020 doi: 10.3390/ijms21186969. [PMID: 32971941.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21186969</ArticleId><ArticleId IdType="pmc">PMC7554794</ArticleId><ArticleId IdType="pubmed">32971941</ArticleId></ArticleIdList></Reference><Reference><Citation>Khawagi W.Y., Al-Kuraishy H.M., Hussein N.R., Al-Gareeb A.I., Atef E., Elhussieny O., Alexiou A., Papadakis M., Jabir M.S., Alshehri A.A., Saad H.M., Batiha G.E. Depression and type 2 diabetes: a causal relationship and mechanistic pathway. Diabetes Obes Metabol. 2024:3031. doi: 10.1111/dom.15630. [PMID: 38802993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.15630</ArticleId><ArticleId IdType="pubmed">38802993</ArticleId></ArticleIdList></Reference><Reference><Citation>Balietti M., Giuli C., Conti F. Peripheral blood brain-derived neurotrophic factor as a biomarker of alzheimer's disease: are there methodological biases? Mol Neurobiol. 2018:6661. doi: 10.1007/s12035-017-0866-y. [PMID: 29330839 10.1007/s12035-017-0866-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0866-y</ArticleId><ArticleId IdType="pmc">PMC6061178</ArticleId><ArticleId IdType="pubmed">29330839</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbalho S.M., Laurindo L.F., de Oliveira Zanuso B., da Silva R.M.S., Gallerani Caglioni L., Nunes Junqueira de Moraes V.B.F., Fornari Laurindo L., Dogani Rodrigues V., da Silva Camarinha Oliveira J., Beluce M.E., Penteado Detregiachi C.R., Barbalho Lamas C., Dos Santos Haber J.F., Cavallari Strozze Catharin V.M., Quesada K., Tanaka M., Valenti V.E. AdipoRon's impact on alzheimer's Disease-A systematic review and meta-analysis. Int J Mol Sci. 2025 doi: 10.3390/ijms26020484. [PMID: 39859201.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms26020484</ArticleId><ArticleId IdType="pmc">PMC11765103</ArticleId><ArticleId IdType="pubmed">39859201</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., Chou R., Glanville J., Grimshaw J.M., Hr&#xf3;bjartsson A., Lalu M.M., Li T., Loder E.W., Mayo-Wilson E., McDonald S., McGuinness L.A., Stewart L.A., Thomas J., Tricco A.C., Welch V.A., Whiting P., Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Revista espanola de cardiologia. 2021:790. doi: 10.1016/j.rec.2021.07.010. (English ed)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rec.2021.07.010</ArticleId><ArticleId IdType="pmc">PMC8008539</ArticleId><ArticleId IdType="pubmed">33781348</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandler J., Cumpston M., Li T., Page M.J., Welch V.J.H.W. 2019. Cochrane handbook for systematic reviews of interventions.</Citation></Reference><Reference><Citation>Wang H., Li S., Zhang J., Peng W., Li T., Zhang J. European journal of medical research; 2024. Efficacy of selective serotonin reuptake inhibitors-related antidepressants in alzheimer's disease: a meta-analysis; p. 438. [PMID: 39210432 10.1186/s40001-024-02006-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-024-02006-z</ArticleId><ArticleId IdType="pmc">PMC11360319</ArticleId><ArticleId IdType="pubmed">39210432</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo M., Abzhandadze T., Hoang M.T., Sacuiu S., Jurado P.G., Pereira J.B., Naia L., Kele J., Maioli S., Xu H., Eriksdotter M., Garcia-Ptacek S. Antidepressant use and cognitive decline in patients with dementia: a national cohort study. BMC Med. 2025:82. doi: 10.1186/s12916-025-03851-3. [PMID: 39994788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-025-03851-3</ArticleId><ArticleId IdType="pmc">PMC11854023</ArticleId><ArticleId IdType="pubmed">39994788</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkumar RPJEoNT . vol. 11. 2024. Resolving a paradox: antidepressants, neuroinflammation, and neurodegeneration.</Citation></Reference><Reference><Citation>Ngcobo N.N. Influence of ageing on the pharmacodynamics and pharmacokinetics of chronically administered medicines in geriatric patients: a review. Clin Pharmacokinet. 2025:335. doi: 10.1007/s40262-024-01466-0. [PMID: 39798015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-024-01466-0</ArticleId><ArticleId IdType="pmc">PMC11954733</ArticleId><ArticleId IdType="pubmed">39798015</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehdi S., Wani S.U.D., Krishna K.L., Kinattingal N., Roohi T.F. A review on linking stress, depression, and insulin resistance via low-grade chronic inflammation. Biochemistry and biophysics reports. 2023 doi: 10.1016/j.bbrep.2023.101571. [PMID: 37965066 10.1016/j.bbrep.2023.101571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrep.2023.101571</ArticleId><ArticleId IdType="pmc">PMC10641573</ArticleId><ArticleId IdType="pubmed">37965066</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukucka T., Ferencova N., Visnovcova Z., Ondrejka I., Hrtanek I., Kovacova V., Macejova A., Mlyncekova Z., Tonhajzerova I. Mechanisms involved in the link between depression, antidepressant treatment, and associated weight change. Int J Mol Sci. 2024 doi: 10.3390/ijms25084511. : [PMID: 38674096 10.3390/ijms25084511.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25084511</ArticleId><ArticleId IdType="pmc">PMC11050075</ArticleId><ArticleId IdType="pubmed">38674096</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdalla M.M.I. Insulin resistance as the molecular link between diabetes and alzheimer's disease. World J Diabetes. 2024:1430. doi: 10.4239/wjd.v15.i7.1430. [PMID: 39099819 10.4239/wjd.v15.i7.1430.</Citation><ArticleIdList><ArticleId IdType="doi">10.4239/wjd.v15.i7.1430</ArticleId><ArticleId IdType="pmc">PMC11292327</ArticleId><ArticleId IdType="pubmed">39099819</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Li Y., Tang Q., Zhang Y., Shao T. Glucose metabolic abnormality: a crosstalk between depression and alzheimer's disease. Curr Neuropharmacol. 2025:757. doi: 10.2174/011570159x343281240912190309. [PMID: 39318215 10.2174/011570159x343281240912190309.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/011570159x343281240912190309</ArticleId><ArticleId IdType="pmc">PMC12163475</ArticleId><ArticleId IdType="pubmed">39318215</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellar D., Craft S. Brain insulin resistance in alzheimer's disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol. 2020:758. doi: 10.1016/s1474-4422(20)30231-3. [PMID: 32730766 10.1016/s1474-4422(20)30231-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(20)30231-3</ArticleId><ArticleId IdType="pmc">PMC9661919</ArticleId><ArticleId IdType="pubmed">32730766</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., Zhang Y., Wen Z., Yang Y., Bu T., Bu X., Ni Q. Cognitive dysfunction in diabetes: abnormal glucose metabolic regulation in the brain. Front Endocrinol. 2023 doi: 10.3389/fendo.2023.1192602. [PMID: 37396164.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2023.1192602</ArticleId><ArticleId IdType="pmc">PMC10312370</ArticleId><ArticleId IdType="pubmed">37396164</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahey J.W., Liu H., Batt H., Panjwani A.A., Tsuji P. Sulforaphane and brain health: from pathways of action to effects on specific disorders. Nutrients. 2025 doi: 10.3390/nu17081353. [PMID: 40284217 10.3390/nu17081353.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu17081353</ArticleId><ArticleId IdType="pmc">PMC12030691</ArticleId><ArticleId IdType="pubmed">40284217</ArticleId></ArticleIdList></Reference><Reference><Citation>Azargoonjahromi A., Nasiri H. CSF Amyloid-&#x3b2;42 associates with neuropsychiatric and cognitive outcomes via cerebral glucose metabolism. Mol Brain. 2025:55. doi: 10.1186/s13041-025-01229-3. [PMID: 40597399 10.1186/s13041-025-01229-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-025-01229-3</ArticleId><ArticleId IdType="pmc">PMC12220793</ArticleId><ArticleId IdType="pubmed">40597399</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x10c;ater M., H&#xf6;lter S.M. A pathophysiological intersection of diabetes and alzheimer's disease. Int J Mol Sci. 2022 doi: 10.3390/ijms231911562. [PMID: 36232867 10.3390/ijms231911562.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231911562</ArticleId><ArticleId IdType="pmc">PMC9569835</ArticleId><ArticleId IdType="pubmed">36232867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kale M.B., Bhondge H.M., Wankhede N.L., Shende P.V., Thanekaer R.P., Aglawe M.M., Rahangdale S.R., Taksande B.G., Pandit S.B., Upaganlawar A.B., Umekar M.J., Kopalli S.R., Koppula S. Navigating the intersection: diabetes and Alzheimer's intertwined relationship. Ageing Res Rev. 2024 doi: 10.1016/j.arr.2024.102415. [PMID: 39002642 10.1016/j.arr.2024.102415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2024.102415</ArticleId><ArticleId IdType="pubmed">39002642</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato N., Morishita R. The roles of lipid and glucose metabolism in modulation of &#x3b2;-amyloid, tau, and neurodegeneration in the pathogenesis of alzheimer disease. Front Aging Neurosci. 2015:199. doi: 10.3389/fnagi.2015.00199. [PMID: 26557086 10.3389/fnagi.2015.00199.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2015.00199</ArticleId><ArticleId IdType="pmc">PMC4615808</ArticleId><ArticleId IdType="pubmed">26557086</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G., Huntley J., Sommerlad A., Ames D., Ballard C., Banerjee S., Brayne C., Burns A., Cohen-Mansfield J., Cooper C., Costafreda S.G., Dias A., Fox N., Gitlin L.N., Howard R., Kales H.C., Kivim&#xe4;ki M., Larson E.B., Ogunniyi A., Orgeta V., Ritchie K., Rockwood K., Sampson E.L., Samus Q., Schneider L.S., Selb&#xe6;k G., Teri L., Mukadam N. Dementia prevention, intervention, and care: 2020 report of the lancet commission. Lancet (London, England) 2020:413. doi: 10.1016/s0140-6736(20)30367-6. [PMID: 32738937 10.1016/s0140-6736(20)30367-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)30367-6</ArticleId><ArticleId IdType="pmc">PMC7392084</ArticleId><ArticleId IdType="pubmed">32738937</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J.Y.C., Yiu K.K.L., Kwok T.C.Y., Wong S.Y.S., Tsoi K.K.F. Depression and antidepressants as potential risk factors in dementia: a systematic review and meta-analysis of 18 longitudinal studies. J Am Med Dir Assoc. 2019:279. doi: 10.1016/j.jamda.2018.12.004. [PMID: 30711460 10.1016/j.jamda.2018.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamda.2018.12.004</ArticleId><ArticleId IdType="pubmed">30711460</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y.C., Tai P.A., Poly T.N., Islam M.M., Yang H.C., Wu C.C., Li Y.J. Increased risk of dementia in patients with antidepressants: a meta-analysis of observational studies. Behav Neurol. 2018 doi: 10.1155/2018/5315098. [PMID: 30123386 10.1155/2018/5315098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/5315098</ArticleId><ArticleId IdType="pmc">PMC6079596</ArticleId><ArticleId IdType="pubmed">30123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Watt J.A., Porter J., Tavilsup P., Chowdhury M., Hatch S., Ismail Z., Kumar S., Kirkham J., Goodarzi Z., Seitz D. Guideline recommendations on behavioral and psychological symptoms of dementia: a systematic review. J Am Med Dir Assoc. 2024:837. doi: 10.1016/j.jamda.2024.03.007. [PMID: 38640961 10.1016/j.jamda.2024.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamda.2024.03.007</ArticleId><ArticleId IdType="pubmed">38640961</ArticleId></ArticleIdList></Reference><Reference><Citation>Quek H.W., Page A., Lee K., Lee G., Hawthorne D., Clifford R., Potter K., Etherton-Beer C. The effect of deprescribing interventions on mortality and health outcomes in older people: an updated systematic review and meta-analysis. Br J Clin Pharmacol. 2024:2409. doi: 10.1111/bcp.16200. [PMID: 39164070 10.1111/bcp.16200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.16200</ArticleId><ArticleId IdType="pubmed">39164070</ArticleId></ArticleIdList></Reference><Reference><Citation>Terstege D.J., Jabeen S., Galea L.A.M., Epp J.R., Sargin D. SSRIs reduce plasma tau and restore dorsal raphe metabolism in alzheimer's disease. Alzheimer's Dementia : the journal of the Alzheimer's Association. 2025 doi: 10.1002/alz.14579. [PMID: 39935329 10.1002/alz.14579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.14579</ArticleId><ArticleId IdType="pmc">PMC11814539</ArticleId><ArticleId IdType="pubmed">39935329</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang K.J., Hong C.H., Lee Y., Lee K.S., Roh H.W., Back J.H., Jung Y.K., Lim K.Y., Noh J.S., Kim H.C., Choi S.H., Kim S.Y., Na D.L., Seo S.W., Lee S., Son S.J. Effect of psychotropic drugs on development of diabetes mellitus in patients with alzheimer's disease. Medicine. 2015 doi: 10.1097/md.0000000000000919. [PMID: 26061313 10.1097/md.0000000000000919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/md.0000000000000919</ArticleId><ArticleId IdType="pmc">PMC4616477</ArticleId><ArticleId IdType="pubmed">26061313</ArticleId></ArticleIdList></Reference><Reference><Citation>Porsteinsson A.P., Drye L.T., Pollock B.G., Devanand D.P., Frangakis C., Ismail Z., Marano C., Meinert C.L., Mintzer J.E., Munro C.A., Pelton G., Rabins P.V., Rosenberg P.B., Schneider L.S., Shade D.M., Weintraub D., Yesavage J., Lyketsos C.G. Effect of citalopram on agitation in alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014:682. doi: 10.1001/jama.2014.93. [PMID: 24549548 10.1001/jama.2014.93.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2014.93</ArticleId><ArticleId IdType="pmc">PMC4086818</ArticleId><ArticleId IdType="pubmed">24549548</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee S., Hellier J., Dewey M., Romeo R., Ballard C., Baldwin R., Bentham P., Fox C., Holmes C., Katona C., Knapp M., Lawton C., Lindesay J., Livingston G., McCrae N., Moniz-Cook E., Murray J., Nurock S., Orrell M., O'Brien J., Poppe M., Thomas A., Walwyn R., Wilson K., Burns A. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet (London, England) 2011:403. doi: 10.1016/s0140-6736(11)60830-1. [PMID: 21764118 10.1016/s0140-6736(11)60830-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(11)60830-1</ArticleId><ArticleId IdType="pubmed">21764118</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg P.B., Drye L.T., Martin B.K., Frangakis C., Mintzer J.E., Weintraub D., Porsteinsson A.P., Schneider L.S., Rabins P.V., Munro C.A., Meinert C.L., Lyketsos C.G. Sertraline for the treatment of depression in alzheimer disease. Am J Geriatr Psychiatr : official journal of the American Association for Geriatric Psychiatry. 2010:136. doi: 10.1097/JGP.0b013e3181c796eb. [PMID: 20087081 10.1097/JGP.0b013e3181c796eb:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JGP.0b013e3181c796eb</ArticleId><ArticleId IdType="pmc">PMC2842121</ArticleId><ArticleId IdType="pubmed">20087081</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith G.S., Kramer E., Ma Y., Hermann C.R., Dhawan V., Chaly T., Eidelberg D. Cholinergic modulation of the cerebral metabolic response to citalopram in alzheimer's disease. Brain : J Neurol. 2009:392. doi: 10.1093/brain/awn326. [PMID: 19153152 10.1093/brain/awn326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn326</ArticleId><ArticleId IdType="pmc">PMC2640217</ArticleId><ArticleId IdType="pubmed">19153152</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouchi Y., Yoshikawa E., Futatsubashi M., Yagi S., Ueki T., Nakamura K. Altered brain serotonin transporter and associated glucose metabolism in alzheimer disease. J Nucl Med : official publication, Society of Nuclear Medicine. 2009:1260. doi: 10.2967/jnumed.109.063008. [PMID: 19617327 10.2967/jnumed.109.063008.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.109.063008</ArticleId><ArticleId IdType="pubmed">19617327</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel S.I., Mintzer J.E., Dysken M., Krishnan K.R., Burt T., McRae T. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatr. 2004:9. doi: 10.1002/gps.998. [PMID: 14716694 10.1002/gps.998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.998</ArticleId><ArticleId IdType="pubmed">14716694</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos C.G., DelCampo L., Steinberg M., Miles Q., Steele C.D., Munro C., Baker A.S., Sheppard J.M., Frangakis C., Brandt J., Rabins P.V. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003:737. doi: 10.1001/archpsyc.60.7.737. [PMID: 12860778 10.1001/archpsyc.60.7.737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.60.7.737</ArticleId><ArticleId IdType="pubmed">12860778</ArticleId></ArticleIdList></Reference><Reference><Citation>Petracca G.M., Chemerinski E., Starkstein S.E. A double-blind, placebo-controlled study of fluoxetine in depressed patients with alzheimer's disease. Int Psychogeriatr. 2001:233. doi: 10.1017/s104161020100761x. [PMID: 11495397 10.1017/s104161020100761x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/s104161020100761x</ArticleId><ArticleId IdType="pubmed">11495397</ArticleId></ArticleIdList></Reference><Reference><Citation>Katona C.L., Hunter B.N., Bray J. A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatr. 1998:100. doi: 10.1002/(sici)1099-1166(199802)13:2&lt;100::aid-gps738&gt;3.0.co;2-j. [PMID: 9526179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(sici)1099-1166(199802)13:2&lt;100::aid-gps738&gt;3.0.co;2-j</ArticleId><ArticleId IdType="pubmed">9526179</ArticleId></ArticleIdList></Reference><Reference><Citation>Taragano F.E., Lyketsos C.G., Mangone C.A., Allegri R.F., Comesa&#xf1;a-Diaz E. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating alzheimer's disease. Psychosomatics. 1997:246. doi: 10.1016/s0033-3182(97)71461-0. [PMID: 9136253 10.1016/s0033-3182(97)71461-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0033-3182(97)71461-0</ArticleId><ArticleId IdType="pubmed">9136253</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>